

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY
CONVEYING PARTY DATA	
Name	Execution Date
U.S. Healthcare I, L.L.C.	02/22/2011
RECEIVING PARTY DATA	
Name:	DrugTech Corporation
Street Address:	300 Delaware Avenue
Internal Address:	Suite 1270
City:	Wilmington
State/Country:	DELAWARE
Postal Code:	19801
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12357622
CORRESPONDENCE DATA	
Fax Number:	(314)231-4342
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	314-345-7000
Email:	uspatents@senniger.com
Correspondent Name:	Senniger Powers LLP
Address Line 1:	100 North Broadway
Address Line 2:	17th Floor
Address Line 4:	St. Louis, MISSOURI 63102
ATTORNEY DOCKET NUMBER:	KVPH 6333.3 (ACW/AXJ)
NAME OF SUBMITTER:	Anita Juric

OP \$40.00 12357622

Total Attachments: 4
 source=01434094#page1.tif
 source=01434094#page2.tif

501445495

PATENT
REEL: 025843 FRAME: 0887

source=01434094#page3.tif

source=01434094#page4.tif

PARTIAL RELEASE OF SECURITY INTEREST IN PATENTS

THIS PARTIAL RELEASE OF SECURITY INTEREST IN PATENTS (this "Partial Release") is made as of February 22, 2011 (the "Effective Date") by **U.S. Healthcare I, LLC** ("U.S. Healthcare I"), a Delaware limited liability company, located at 375 Park Avenue, 12th Floor, New York, New York 10152, as administrative and collateral agent (in such capacity, together with its successors and permitted assigns, the "Agent") in favor of **DrugTech Corporation**, a Delaware corporation, located at 300 Delaware Avenue, Suite 1270, Wilmington, Delaware 19801 (the "Grantor"). Capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Note (as defined below), Credit Agreement (as defined below) or the Security Agreement (as defined below) as the case may be.

WHEREAS, reference is made to that certain Promissory Note and Security Agreement dated as of September 13, 2010 (as amended, restated, supplemented, or otherwise modified from time to time, the "Note"), by and among **K-V PHARMACEUTICAL COMPANY** (the "Borrower"), its domestic subsidiaries, and the Agent;

WHEREAS, reference is made to (i) that certain Credit and Guaranty Agreement dated as of November 17, 2010 (as amended, restated, supplemented or otherwise modified from time to time, the "Credit Agreement") among Borrower, Grantor, the Agent and the lender parties thereto from time to time (collectively, the "Lenders" and, together with the Agent, the "Secured Parties"), and (ii) that certain Pledge and Security Agreement dated November 17, 2010 (as amended, restated, supplemented or otherwise modified from time to time, the "Security Agreement") entered into between Borrower, Grantor, certain other subsidiaries of the Borrower, and the Agent for the benefit of the Secured Parties;

WHEREAS, pursuant to the Note, Grantor executed and delivered to the Agent that certain Patent Security Agreement dated September 13, 2010 (the "Note Patent Security Agreement") in favor of the Agent for the benefit of the Secured Parties;

WHEREAS, pursuant to the Security Agreement, Grantor executed and delivered to the Agent that certain Patent Security Agreement dated November 17, 2010 (the "Bridge Patent Security Agreement") in favor of the Agent for the benefit of the Secured Parties;

WHEREAS, pursuant to the terms and conditions of the Note Patent Security Agreement and the Bridge Patent Security Agreement, Grantor pledged and granted to the Agent, to secure the obligations under the Note and Security Agreement, respectively, a continuing security interest in all of such Grantor's right, title and interest in and to the Patent Collateral (as defined in each of the Note Patent Security Agreement and the Bridge Patent Security Agreement);

WHEREAS, the Note Patent Security Agreement was recorded with the United States Patent and Trademark Office on September 14, 2010 at Reel/Frame 024982/0344;

WHEREAS, the Bridge Patent Security Agreement was recorded with the United States Patent and Trademark Office on November 20, 2010 at Reel/Frame 025385/0498; and

WHEREAS, Grantor has requested that the Agent release its continuing security interest granted pursuant to the Note Patent Security Agreement and the Bridge Patent Security Agreement in and to the Patent Collateral pertaining solely to that certain patent application set forth on Schedule A hereto (the "Released Patent Collateral").

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent, on behalf of the Secured Parties and itself, hereby terminates, cancels and releases as of the Effective Date its continuing security interest granted in and to the Released Patent Collateral pursuant to the Note Patent Security Agreement and the Bridge Patent Security Agreement and hereby assigns and transfers to the Grantor any right, title and interest it may have in and to the Released Patent Collateral pursuant to the Note Patent Security Agreement and the Bridge Patent Security Agreement.

The release set forth herein shall be without recourse to or warranty by the Agent and shall relate solely to the Released Patent Collateral.


THIS PARTIAL RELEASE SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.

* * * * *

IN WITNESS WHEREOF, the Agent has caused this Partial Release to be executed by its duly authorized representative as of the Effective Date.

AGENT:

U.S. HEALTHCARE I, L.L.C.


.....

Name: Kevin Furco

Title: Authorized Signatory

ACKNOWLEDGED AND AGREED BY:

DRUGTECH CORPORATION

A handwritten signature in cursive script, appearing to read "Bradley S. Schammel", is written over a horizontal line.

Name: Bradley S. Schammel

Title: Assistant Secretary

SCHEDULE A

(Reel/Frame 024982/0334 and Reel/Frame 025385/0498)

Title	App. No.	Filing Date	Owner
Transgenic Plants Expressing Cobalamin Binding Proteins	12/357622	1/22/09	DrugTech Corporation